Examkin

Soru

Zorluk: OrtaHematology and Oncology

A 22-year-old woman presents to the clinic for evaluation of easy bruising and prolonged bleeding following minor cuts. She reports a history of heavy menses since menarche, which occasionally requires iron supplementation. Her mother experiences similar mucosal bleeding symptoms. Physical examination reveals several small ecchymoses on her lower extremities but no petechiae. Vital signs are within normal limits. Arrange the following clinical steps in the most appropriate chronological sequence for the diagnostic workup and management of this patient's most likely condition.

  1. 1Obtain initial screening tests, including a complete blood count, prothrombin time, and activated partial thromboplastin time.
  2. 2Measure von Willebrand factor (vWF) antigen, vWF activity (ristocetin cofactor), and Factor VIII activity.
  3. 3Perform vWF multimer analysis and specialized platelet aggregation studies to definitively classify the disease subtype.
  4. 4Administer a desmopressin (DDAVP) challenge test to verify adequate therapeutic response and safety.
  5. 5Implement a tailored prophylactic treatment plan utilizing DDAVP or factor concentrates prior to future invasive procedures.

Cevap

The correct sequence begins with basic screening tests, followed by specific diagnostic assays to confirm von Willebrand disease. Next, subtyping is performed, followed by a DDAVP therapeutic challenge, and finally, the implementation of a prophylactic plan.
The diagnostic approach to a suspected bleeding disorder must proceed sequentially from general to specific to ensure both accuracy and patient safety. 1) Initial screening (CBC, PT, aPTT) is essential to rule out platelet disorders and identify general pathway defects. 2) Because the clinical picture strongly suggests von Willebrand disease, specific assays (vWF antigen, ristocetin cofactor, FVIII) are measured next to confirm the diagnosis. 3) Once confirmed, the disease must be subtyped using multimer analysis and platelet aggregation studies. This is a critical safety step because management differs significantly by subtype. 4) After subtyping rules out Type 2B (in which DDAVP can cause transient thrombocytopenia), a DDAVP challenge is performed to confirm the patient has an adequate biological response. 5) Finally, with all diagnostic and therapeutic data gathered, a tailored prophylactic regimen can be safely established for future surgical or dental procedures.

Adım Adım Çözüm

1
Obtain initial screening tests, including a complete blood count, prothrombin time, and activated partial thromboplastin time.
Rules out simple thrombocytopenia and evaluates baseline coagulation pathways.
This is the standard first step for any patient presenting with a suspected bleeding diathesis to safely narrow the differential diagnosis.
2
Measure von Willebrand factor (vWF) antigen, vWF activity (ristocetin cofactor), and Factor VIII activity.
Confirms the diagnosis of von Willebrand disease (vWD).
Given the patient's mucocutaneous bleeding history and family history, vWD is highly suspected. These specific assays quantify the amount and function of vWF.
3
Perform vWF multimer analysis and specialized platelet aggregation studies to definitively classify the disease subtype.
Distinguishes between Type 1, Type 2 variants (including 2B), and Type 3 vWD.
Classification is critical because the subtype directly dictates which therapies are safe and effective. For instance, DDAVP can be dangerous in certain subtypes.
4
Administer a desmopressin (DDAVP) challenge test to verify adequate therapeutic response and safety.
Determines if the patient will have a sufficient endogenous rise in vWF levels for minor procedures.
Once Type 2B is ruled out via subtyping, a challenge test is necessary to ensure DDAVP is a viable prophylactic option for this specific patient.
5
Implement a tailored prophylactic treatment plan utilizing DDAVP or factor concentrates prior to future invasive procedures.
Prevents severe bleeding complications during future surgeries or dental work.
This is the ultimate clinical management goal, formulated safely based on the complete diagnostic and subtyping workup.

Anahtar Kavram

The diagnostic workup and management of von Willebrand disease requires a stepwise approach: initial screening, confirmatory functional assays, subtyping to ensure treatment safety, a therapeutic challenge, and finally tailored prophylaxis.
Tahmini Süre:2m 0s
Bu soruyu puanla

Konular

Hematology and Oncology

Bu konudan daha fazla soru